-葡萄糖共运输体-2 抑制剂对骨肌肉的影响
Claudia Stöllberger1, Josef Finsterer2, Birke Schneider3
1Institut Gesünder Leben, Vienna, Austria.
European journal of internal medicine
|July 24, 2025
概括
如今,-葡萄糖-同载体2抑制剂 (SGLT2i),如empagliflozin和dapagliflozin,用于治疗心力衰竭. 对其骨肌效应的研究显示,数据有限且相互矛盾,需要在不同患者群体进行进一步的研究.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 肌肉生理学 肌肉生理学
背景情况:
- 在非糖尿病患者中,-葡萄糖-同载体2-抑制剂 (SGLT2i) 越来越多地用于心力衰竭 (HF).
- 担心对骨肌肉的潜在不良影响,特别是肌肉病和肉病,需要进行调查.
研究的目的:
- 审查关于empagliflozin和dapagliflozin对患者骨肌肉的影响的现有文献,包括患有和没有糖尿病的患者.
- 识别当前研究中的差距,并突出未来研究的领域.
主要方法:
- 在PubMed上进行了系统的文献搜索,使用与SGLT2抑制剂,特定药物名称和骨肌状况相关的关键词.
- 如果这些研究是评论,社论,协议,信件或体外/体内研究,则被排除在外.
- 数据提取的重点是报告的肌肉病变/肌肉分裂,肉,肌肉质量变化和身体表现的病例.
主要成果:
- 报告了很少的肌肉病变/肌肉分裂病例,其中一些与他类药物使用有关;然而,研究没有发现SGLT2i-他类药物组合的风险增加.
- 对SGLT2i相关的肉症的研究通常涉及小群体,主要是糖尿病患者和日本人,观察时间有限.
- 关于肌肉质量变化的数据存在争议,一些研究显示肌肉质量下降,而另一些则显示肌肉质量没有变化. 肌肉活检表明了代谢变化和肌纤维缩,但没有明显的功能相关性.
结论:
- 目前关于SGLT2抑制剂对骨肌肉的影响的数据有限且相互矛盾.
- 迫切需要进一步的研究,特别是在非糖尿病,非日本和心力衰竭患者群体.
- 较长的观察期 (>12个月) 对于准确评估随着时间的推移发展的肉类的风险至关重要.
相关概念视频
Secondary Active Transport
124.5K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
124.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
304
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
304
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
263
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
263
Dipeptidyl Peptidase 4 Inhibitors
261
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
261
Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
Glucose Absorption Into the Small Intestine
32.4K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.4K


